RESTANTE, GIULIANA Statistiche
RESTANTE, GIULIANA
DIPARTIMENTO DI RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
Genome Wide Association Studies (GWAS)
In corso di stampa Restante, Giuliana; Arrigoni, Elena; Del Re, Marzia; Di Paolo, Antonello; Danesi, Romano
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers
2020-01-01 Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M.
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers
2019-01-01 Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M.
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring
2019-01-01 Pasqualetti, Francesco; Restante, Giuliana; Gonnelli, Alessandra; Rofi, Eleonora; Molinari, Alessandro; Crucitta, Stefania; Paiar, Fabiola; Rudà, Roberta; Danesi, Romano; Soffietti, Riccardo; Del Re, Marzia
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy
2019-01-01 Crucitta, S.; Restante, G.; Del Re, M.; Bertolini, I.; Bona, E.; Rofi, E.; Fontanelli, L.; Gianfilippo, G.; Fogli, S.; Stasi, I.; Ghilli, M.; Fontana, A.; Danesi, R.
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
2019-01-01 Bordi, Paola; Del Re, Marzia; Minari, Roberta; Rofi, Eleonora; Buti, Sebastiano; Restante, Giuliana; Squadrilli, Anna; Crucitta, Stefania; Casartelli, Chiara; Gnetti, Letizia; Azzoni, Cinzia; Bottarelli, Lorena; Petrini, Iacopo; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Danesi, Romano; Tiseo, Marcello
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
2019-01-01 Del Re, Marzia; Crucitta, Stefania; Gianfilippo, Giulia; Passaro, Antonio; Petrini, Iacopo; Restante, Giuliana; Michelucci, Angela; Fogli, Stefano; de Marinis, Filippo; Porta, Camillo; Chella, Antonio; Danesi, Romano
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
2018-01-01 Arrigoni, Elena; Del Re, Marzia; Galimberti, Sara; Restante, Giuliana; Rofi, Eleonora; Crucitta, Stefania; Baratè, Claudia; Petrini, Mario; Danesi, Romano; Di Paolo, Antonello
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells
2018-01-01 Del Re, Marzia; Arrigoni, Elena; Restante, Giuliana; Passaro, Antonio; Rofi, Eleonora; Crucitta, Stefania; De Marinis, Filippo; Di Paolo, Antonello; Danesi, Romano
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
2018-01-01 DEL RE, Marzia; Marconcini, Riccardo; Pasquini, Giulia; Rofi, Eleonora; Vivaldi, Caterina; Bloise, Francesco; Restante, Giuliana; Arrigoni, Elena; Caparello, Chiara; Grazia Bianco, Maria; Crucitta, Stefania; Petrini, Iacopo; Vasile, Enrico; Falcone, Alfredo; Danesi, Romano
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment
2018-01-01 Del Re, Marzia; Crucitta, Stefania; Restante, Giuliana; Rofi, Eleonora; Arrigoni, Elena; Biasco, Elisa; Sbrana, Andrea; Coppi, Erika; Galli, Luca; Bracarda, Sergio; Santini, Daniele; Danesi, Romano
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
2018-01-01 Del Re, Marzia; Bordi, Paola; Rofi, Eleonora; Restante, Giuliana; Valleggi, Simona; Minari, Roberta; Crucitta, Stefania; Arrigoni, Elena; Chella, Antonio; Morganti, Riccardo; Tiseo, Marcello; Petrini, Iacopo; Danesi, Romano
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors
2017-01-01 Antonuzzo, L.; DEL RE, Marzia; Barucca, V.; Spada, F.; Meoni, G.; Restante, G.; Danesi, R.; Di Costanzo, F.; Fazio, N.
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment
2017-01-01 Bordi, Paola; Tiseo, Marcello; Rofi, Eleonora; Petrini, Iacopo; Restante, Giuliana; Danesi, Romano; DEL RE, Marzia
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
2017-01-01 Del Re, Marzia; Rofi, Eleonora; Restante, Giuliana; Crucitta, Stefania; Arrigoni, Elena; Fogli, Stefano; Di Maio, Massimo; Petrini, Iacopo; Danesi, Romano
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
2017-01-01 Del Re, M; Bordi, P; Petrini, I; Rofi, Eleonora; Mazzoni, Fabrizia; Belluomini, L; Vasile, Enrico; Restante, Giuliana; Di Costanzo, F; Falcone, A; Frassoldati, A; van Schaik, Rhn; Steendam, Cmj; Chella, A; Tiseo, M; Morganti, R; Danesi, R.
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase.
2017-01-01 Del Re, M; Restante, G; Di Paolo, A; Crucitta, S; Rofi, E; Danesi, R.
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment
2017-01-01 Del Re, Marzia; Latiano, Tiziana; Fidilio, Leonardo; Restante, Giuliana; Morelli, Franco; Maiello, Evaristo; Danesi, Romano
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Genome Wide Association Studies (GWAS) | In corso di stampa | Restante, Giuliana; Arrigoni, Elena; Del Re, Marzia; Di Paolo, Antonello; Danesi, Romano | |
| Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers | 1-gen-2020 | Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M. | |
| Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers | 1-gen-2019 | Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M. | |
| Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring | 1-gen-2019 | Pasqualetti, Francesco; Restante, Giuliana; Gonnelli, Alessandra; Rofi, Eleonora; Molinari, Alessandro; Crucitta, Stefania; Paiar, Fabiola; Rudà, Roberta; Danesi, Romano; Soffietti, Riccardo; Del Re, Marzia | |
| Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy | 1-gen-2019 | Crucitta, S.; Restante, G.; Del Re, M.; Bertolini, I.; Bona, E.; Rofi, E.; Fontanelli, L.; Gianfilippo, G.; Fogli, S.; Stasi, I.; Ghilli, M.; Fontana, A.; Danesi, R. | |
| From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC | 1-gen-2019 | Bordi, Paola; Del Re, Marzia; Minari, Roberta; Rofi, Eleonora; Buti, Sebastiano; Restante, Giuliana; Squadrilli, Anna; Crucitta, Stefania; Casartelli, Chiara; Gnetti, Letizia; Azzoni, Cinzia; Bottarelli, Lorena; Petrini, Iacopo; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Danesi, Romano; Tiseo, Marcello | |
| Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy | 1-gen-2019 | Del Re, Marzia; Crucitta, Stefania; Gianfilippo, Giulia; Passaro, Antonio; Petrini, Iacopo; Restante, Giuliana; Michelucci, Angela; Fogli, Stefano; de Marinis, Filippo; Porta, Camillo; Chella, Antonio; Danesi, Romano | |
| Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment | 1-gen-2018 | Arrigoni, Elena; Del Re, Marzia; Galimberti, Sara; Restante, Giuliana; Rofi, Eleonora; Crucitta, Stefania; Baratè, Claudia; Petrini, Mario; Danesi, Romano; Di Paolo, Antonello | |
| Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells | 1-gen-2018 | Del Re, Marzia; Arrigoni, Elena; Restante, Giuliana; Passaro, Antonio; Rofi, Eleonora; Crucitta, Stefania; De Marinis, Filippo; Di Paolo, Antonello; Danesi, Romano | |
| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC | 1-gen-2018 | DEL RE, Marzia; Marconcini, Riccardo; Pasquini, Giulia; Rofi, Eleonora; Vivaldi, Caterina; Bloise, Francesco; Restante, Giuliana; Arrigoni, Elena; Caparello, Chiara; Grazia Bianco, Maria; Crucitta, Stefania; Petrini, Iacopo; Vasile, Enrico; Falcone, Alfredo; Danesi, Romano | |
| Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment | 1-gen-2018 | Del Re, Marzia; Crucitta, Stefania; Restante, Giuliana; Rofi, Eleonora; Arrigoni, Elena; Biasco, Elisa; Sbrana, Andrea; Coppi, Erika; Galli, Luca; Bracarda, Sergio; Santini, Daniele; Danesi, Romano | |
| The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response | 1-gen-2018 | Del Re, Marzia; Bordi, Paola; Rofi, Eleonora; Restante, Giuliana; Valleggi, Simona; Minari, Roberta; Crucitta, Stefania; Arrigoni, Elena; Chella, Antonio; Morganti, Riccardo; Tiseo, Marcello; Petrini, Iacopo; Danesi, Romano | |
| Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors | 1-gen-2017 | Antonuzzo, L.; DEL RE, Marzia; Barucca, V.; Spada, F.; Meoni, G.; Restante, G.; Danesi, R.; Di Costanzo, F.; Fazio, N. | |
| Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment | 1-gen-2017 | Bordi, Paola; Tiseo, Marcello; Rofi, Eleonora; Petrini, Iacopo; Restante, Giuliana; Danesi, Romano; DEL RE, Marzia | |
| Implications of KRAS mutations in acquired resistance to treatment in NSCLC | 1-gen-2017 | Del Re, Marzia; Rofi, Eleonora; Restante, Giuliana; Crucitta, Stefania; Arrigoni, Elena; Fogli, Stefano; Di Maio, Massimo; Petrini, Iacopo; Danesi, Romano | |
| Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment | 1-gen-2017 | Del Re, M; Bordi, P; Petrini, I; Rofi, Eleonora; Mazzoni, Fabrizia; Belluomini, L; Vasile, Enrico; Restante, Giuliana; Di Costanzo, F; Falcone, A; Frassoldati, A; van Schaik, Rhn; Steendam, Cmj; Chella, A; Tiseo, M; Morganti, R; Danesi, R. | |
| Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. | 1-gen-2017 | Del Re, M; Restante, G; Di Paolo, A; Crucitta, S; Rofi, E; Danesi, R. | |
| Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment | 1-gen-2017 | Del Re, Marzia; Latiano, Tiziana; Fidilio, Leonardo; Restante, Giuliana; Morelli, Franco; Maiello, Evaristo; Danesi, Romano |